Balanced news tone
News Sentiment
NTLA sentiment intelligence
Intellia Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
35 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+29.4% over one week, +24.4% over four weeks, trend active, and near fair-value range.
Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
29.4%
Price confirming higher
Trend fit
Trend active
24.4% over four weeks
Fair value
-18.1%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
20
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stocktwits
Direct company coverage
Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 22 Jun 2026 08:45
- Source
- Stocktwits
Kavout
Direct company coverage
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 22:42
- Source
- Kavout
simplywall.st
Direct company coverage
Intellia Therapeutics (NTLA) Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 20:21
- Source
- simplywall.st
Motley Fool
Direct company coverage
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 20 Jun 2026 15:22
- Source
- Motley Fool
simplywall.st
Direct company coverage
Intellia Therapeutics (NTLA) Stock Could Be 41.2% Undervalued After Phase 3 HAE Data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 23:33
- Source
- simplywall.st
GuruFocus
Direct company coverage
Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Jun 2026 19:42
- Source
- GuruFocus
Market source
Direct company coverage
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 12:43
- Source
- Market source
Insider Monkey
Direct company coverage
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jun 2026 02:46
- Source
- Insider Monkey
Investor's Business Daily
Direct company coverage
Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 15 Jun 2026 21:10
- Source
- Investor's Business Daily
Benzinga
Direct company coverage
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 15 Jun 2026 13:39
- Source
- Benzinga
GlobeNewswire
Direct company coverage
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 13 Jun 2026 11:30
- Source
- GlobeNewswire
simplywall.st
Direct company coverage
A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 05 Jun 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 31 May 2026 07:00
- Source
- Seeking Alpha
TradingView
Direct company coverage
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 18:32
- Source
- TradingView
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 07:00
- Source
- simplywall.st
Intellia Therapeutics
Direct company coverage
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Intellia Therapeutics
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Is Intellia Therapeutics (NTLA) Pricing Reflect Its Gene Editing Potential After Recent Price Surge
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Barchart.com
Direct company coverage
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Barchart.com
Intellia Therapeutics
Direct company coverage
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Apr 2026 07:00
- Source
- Intellia Therapeutics
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
The Globe and Mail
Direct company coverage
Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Apr 2026 07:00
- Source
- The Globe and Mail
Market source
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Market source
Intellia Therapeutics
Direct company coverage
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- Intellia Therapeutics